The YTHDF2 inhibitor DC-Y13-27 enhances the anti-tumor effects of radiotherapy and radio-immunotherapy by mimicking the phenotypic consequences of YTHDF2 loss, which include altered MDSC differentiation, suppressed intra-tumoral trafficking, and attenuated immunosuppressive activity270. The gene discussed is YTHDF2; the disease is neoplasm.